|
業務類別
|
Biotechnology |
|
業務概覽
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more linesof systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed byEurope, the Middle East and Africa (EMEA). |
| 公司地址
| Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066 |
| 電話號碼
| +41 216530200 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.adctherapeutics.com |
| 員工數量
| 265 |
| Mr. Mohamed Zaki, M.D.,PhD |
Chief Medical Officer |
美元 670.02K |
21/04/2025 |
| Mr. Peter J. Graham |
Chief Legal Officer |
-- |
21/04/2025 |
| Mr. Jose Carmona |
Chief Financial Officer |
美元 505.01K |
10/03/2026 |
| Ms. Lisa Michelle Kallebo |
Corporate Controller and Chief Accounting Officer |
-- |
10/03/2026 |
| Mr. Ameet Mallik |
Chief Executive Officer and Director |
美元 746.24K |
10/03/2026 |
|
|
| Mr. Robert W. Azelby |
Independent Director |
10/03/2026 |
| Dr. Jean-Pierre Bizzari, M.D. |
Independent Director |
10/03/2026 |
| Mr. Ron Squarer |
Chairman of the Board |
10/03/2026 |
| Dr. Victor Sandor, C.M.,PhD |
Independent Director |
10/03/2026 |
| Dr. Tyrell J. Rivers, PhD |
Independent Director |
10/03/2026 |
| Ms. Viviane Monges |
Independent Director |
10/03/2026 |
| Mr. Peter Hug, PhD |
Lead Independent Director |
10/03/2026 |
| Mr. Thomas Pfisterer |
Director |
21/04/2025 |
| Mr. Timothy P. Coughlin |
Director |
10/03/2026 |
| Mr. Ameet Mallik |
Chief Executive Officer and Director |
10/03/2026 |
|
|
|
|
